Patient characteristics: LKT population
| Characteristic . | Patients groups according to follow-up period . | ||
|---|---|---|---|
| Less than 1 y . | 1 to 5 y . | More than 5 y . | |
| Patients, no. | 14 | 18 | 12 |
| Demography | |||
| Sex, M/F | 11/3 | 10/8 | 8/4 |
| Age, y | 56.9 ± 7.8 | 56 ± 7.2 | 49.8 ± 11.1 |
| Follow-up period, mo | 4.9 ± 2.2 | 33.4 ± 14.3 | 100.2 ± 31.9 |
| Medical indication for the transplantation | |||
| Viral cirrhosis | 9 (64.3) | 7 (38.9) | 6 (50) |
| Alcoholic cirrhosis | 4 (28.6) | 3 (16.7) | 2 (16.7) |
| Hyperoxaluria type 1/amyloidosis neuropathy | 0 | 2 (11.1) | 3 (25) |
| Liver-kidney polykystosis | 1 (7.1) | 3 (16.7) | 0 |
| Other | 0 | 3 (16.7) | 1 (8.3) |
| Viral hepatic recurrence | |||
| Hepatitis B virus | 1 (7.1) | 0 | 1 (8.3) |
| Hepatitis C virus | 3 (21.4) | 4 (22.2) | 2 (16.7) |
| Immunosuppressive treatment | |||
| Cyclosporin A | 0 | 3 (16.7) | 4 (33.3) |
| FK506 | 13 (92.8) | 14 (77.8) | 4 (33.3) |
| Corticosteroid | 8 (57.1) | 7 (38.9) | 10 (83.3) |
| Mycophenolate mofetil | 6 (42.8) | 7 (38.9) | 4 (33.3) |
| Azathioprin | 0 | 0 | 3 (25) |
| Everolimus | 1 (7.1) | 1 (5.6) | 1 (8.3) |
| sHLA-G, ng/mL | |||
| sHLA-G1 + HLA-G5 | 251.4 ± 88.8 | 214.3 ± 108.9 | 238.5 ± 139.2 |
| HLA-G5 | 102.1 ± 45.3 | 95.3 ± 48.0 | 116.8 ± 61.5 |
| Rejection | |||
| Acute rejection | 0 | 1 (5.6) | 0 |
| Chronic rejection | 0 | 0 | 0 |
| Characteristic . | Patients groups according to follow-up period . | ||
|---|---|---|---|
| Less than 1 y . | 1 to 5 y . | More than 5 y . | |
| Patients, no. | 14 | 18 | 12 |
| Demography | |||
| Sex, M/F | 11/3 | 10/8 | 8/4 |
| Age, y | 56.9 ± 7.8 | 56 ± 7.2 | 49.8 ± 11.1 |
| Follow-up period, mo | 4.9 ± 2.2 | 33.4 ± 14.3 | 100.2 ± 31.9 |
| Medical indication for the transplantation | |||
| Viral cirrhosis | 9 (64.3) | 7 (38.9) | 6 (50) |
| Alcoholic cirrhosis | 4 (28.6) | 3 (16.7) | 2 (16.7) |
| Hyperoxaluria type 1/amyloidosis neuropathy | 0 | 2 (11.1) | 3 (25) |
| Liver-kidney polykystosis | 1 (7.1) | 3 (16.7) | 0 |
| Other | 0 | 3 (16.7) | 1 (8.3) |
| Viral hepatic recurrence | |||
| Hepatitis B virus | 1 (7.1) | 0 | 1 (8.3) |
| Hepatitis C virus | 3 (21.4) | 4 (22.2) | 2 (16.7) |
| Immunosuppressive treatment | |||
| Cyclosporin A | 0 | 3 (16.7) | 4 (33.3) |
| FK506 | 13 (92.8) | 14 (77.8) | 4 (33.3) |
| Corticosteroid | 8 (57.1) | 7 (38.9) | 10 (83.3) |
| Mycophenolate mofetil | 6 (42.8) | 7 (38.9) | 4 (33.3) |
| Azathioprin | 0 | 0 | 3 (25) |
| Everolimus | 1 (7.1) | 1 (5.6) | 1 (8.3) |
| sHLA-G, ng/mL | |||
| sHLA-G1 + HLA-G5 | 251.4 ± 88.8 | 214.3 ± 108.9 | 238.5 ± 139.2 |
| HLA-G5 | 102.1 ± 45.3 | 95.3 ± 48.0 | 116.8 ± 61.5 |
| Rejection | |||
| Acute rejection | 0 | 1 (5.6) | 0 |
| Chronic rejection | 0 | 0 | 0 |
Patients (n = 44) were separated into 3 groups based on the time interval between the date of the transplantation and the blood sampling to measure sHLA-G plasma levels. Data are means plus or minus SD or number of patients (%). There was no significant difference in sHLA-G plasma levels between follow-up period groups.